A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Recruiting

Phase 3

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Sponsor:

Minoryx Therapeutics, S.L.

Code:

NCT05819866

Conditions

Cerebral Adrenoleukodystrophy (cALD)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Leriglitazone

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-30. This information was provided to ClinicalTrials.gov by Minoryx Therapeutics, S.L. on 2025-04-08.